ArticleSignal transduction and targeted therapy2026
A nanobody-based proteolysis-targeting chimera offers broad-spectrum protection against diverse influenza virus infections.
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epidemiological and Phylogenetic Analysis of Reassorted H10Nx Avian Influenza Viruses in Guangdong Province, China.Influenza and other respiratory viruses · 2026Article
- Ubiquitin-Dependent Regulation of Influenza A Virus Polymerase and vRNP Function: Mechanisms and Therapeutic Opportunities.Microorganisms · 2026Review
- Antiviral Resistance in Influenza: Clinical and Public Health Implications.Influenza and other respiratory viruses · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Influenza A viruses continue to pose a major threat to global public health. In addition to H1N1 and H3N2 subtypes causing seasonal epidemics that result in an estimated 3-5 million severe cases and 290,000-650,000 deaths annually, other subtypes, including avian H5, H7, and H9, have shown cross-species transmission potential, leading to thousands of human infections in multiple countries. The development of broad-spectrum antiviral drugs capable of inhibiting different influenza virus subtypes is key for alleviating the severity of diseases caused by influenza viruses and reducing mortality rates. Here, we constructed five nanobody-based proteolysis-targeting chimeras (Nb-PROTACs) by fusing NP-specific nanobodies to the α-domain of the Von Hippel‒Lindau (VHL) E3 ubiquitin ligase. We found that two of these chimeras (VHL-Nb135 and VHL-Nb170) efficiently induced NP degradation across all 16 recognized influenza A subtypes (H1-H16). VHL-Nb135 and VHL-Nb170 efficiently inhibited the replication of human (H1N1, H3N2) and avian (H5N1, H7N9, H9N2) influenza viruses in vitro. In animal studies, when VHL-Nb170 was administered intratracheally to mice via adeno-associated virus serotype LungM3 (AAV-LungM3), virus replication was significantly inhibited in the respiratory tract, and 90% and 80% of the mice survived infection with lethal H1N1 and H5N1 viruses, respectively. Our study indicates that Nb-PROTACs offer a robust platform for the development of broad-spectrum therapies against influenza viruses and hold potential for clinical translation as innovative antiviral candidate drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.